Entera Bio Ltd. (ENTX) Names Ramesh Ratan CFO

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of veteran finance and operations executive Ramesh Ratan as U.S. Chief Financial Officer. Mr. Ratan replaces Jonathan Lieber who was serving as Entera’s interim U.S. CFO.

Mr. Ratan brings 40 years of experience at biomedical, tech, and Fortune 500 companies in senior, executive, vice president, and C-level positions. He was most recently CFO, Head of Manufacturing, and Corporate Secretary at AOBiome. He served as CFO at Xcellerex, Enanta Pharmaceuticals, Repligen, and held positions at Bristol-Myers Squibb, American Superconductor, and Equinox Solutions. As CFO, he raised over $300 million and negotiated numerous value enhancing strategic alliances and corporate transactions. In operations and manufacturing roles, he was instrumental in implementing GMP, scaling up, and improving efficiencies.

“Ramesh is a seasoned financial executive with deep experience in manufacturing and operations. A strategic thinker with a solid track record in managing growth, Ramesh complements and strengthens Entera’s management team. I have worked with him for many years at prior biopharma companies and look forward to teaming up with him again to leverage Entera’s platform through the clinic and into the hands of patients in need of effective oral drugs,” stated Entera CEO Spiros Jamas. “We thank Jon for his excellent service during a pivotal time for Entera and wish him well.”

You May Also Be Interested In

• Lowe's names five executive vice presidents effective Sept. 1
• Venture Global closes $3B revolving credit facility for LNG expansion
• Destination XL Group names Jimmy Olsson as chief growth officer